A Phase 2 Study of Sacituzumab Govitecan Plus Cetuximab in People With Head and Neck Squamous Cell Cancer

Full Title

A Phase II Study of Sacituzumab Govitecan in Combination with Cetuximab in Patients with Recurrent Metastatic HNSCC That Has Progressed After First Line Therapy

Purpose

Researchers are assessing the combination of sacituzumab govitecan and cetuximab for treating head and neck cancer. The people in this study have squamous cell cancer of the head and neck. Their cancer came back or spread after prior treatment.

Sacituzumab govitecan is an antibody that binds to proteins on cancer cells. Once there, it releases a drug that enters the cells and kills them. Cetuximab blocks a protein called EGFR, which can cause tumors to grow. It is already used to treat head and neck cancer. Both drugs are given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must

• Have head and neck squamous cell carcinoma that came back or spread after one or two prior regimens of therapy.
• Have completed previous anti-cancer treatment at least 2 weeks before getting the study treatment.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Winston Wong’s office at 646-608-4245.